The presence of the IDH mutation in glioma raises the possibility that these CNS malignancies could be targeted with metabolic-based therapeutics, however, the exploration of the role that regulatory lipids, such as sphingolipids serve within the IDH1mut gliomas remains limited. The gene discussed is IDH2; the disease is central nervous system cancer.